Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T

John Carroll

Editor & Founder

Ten months after the FDA took the shackles off Poseida’s study for a CAR-T directed against castrate-resistant prostate cancer, the executive team is now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Mov­ing past a pa­tient death, Po­sei­da of­fers an ear­ly snap­shot of proof of ef­fi­ca­cy for a next-gen sol­id tu­mor CAR-T

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T